The FDA approved Novartis’ Kisqali in combination with hormone therapy for certain early-stage breast cancers, expanding patient access to the drug. Kisqali targets proteins CDK4 and 6, which can promote cancer cell growth. This approval allows patients without positive lymph nodes to receive CDK4/6 inhibitors, offering a new treatment option. Kisqali, taken for three years after surgery, can reduce the risk of recurrence by 28.5%. Side effects include low white blood cell counts and joint pain. Early detection is important, as earlier-stage breast cancers can often be effectively treated without the need for CDK4/6 inhibitors or chemotherapy.
Source link
FDA OK’s expansion of Novartis breast cancer therapy
